Servier Boosts Presence in Rare Cancers With $2.5B Acquisition of Day One Biopharma

Дата публикации: 09-03-2026 17:00:00

Day One markets Ojemda, approved for treating pediatric low-grade glioma, the most common type of brain cancer in children.Continue reading

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Neurocrine’s $2.9B Soleno Buyout Brings What Could Become Its Next Blockbuster Drug	5	7	07-04-2026
2	Gilead’s Pipeline Strategy Takes Shape With $3B Acquisition of Cancer Biotech Tubulis	0	5	08-04-2026
3	Why Biogen Is Paying $5.6B to Buy Apellis Pharma	0	5	03-04-2026
4	eMed, Nitra Secure Hundreds of Millions in Funding	0	5	06-04-2026
5	New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer	5	7	02-07-2026
6	New targeted therapy shows promising early results in advanced pancreatic cancer	2	7	05-07-2026
7	New experimental approach may help overcome drug resistance in deadly brain cancer	5	8	09-07-2026
8	FDA Approves Datopotamab Deruxtecan-dlnk for Unresectable or Metastatic TNBC	5	7	24-06-2026
9	GA-Renova & CCA in race to buy American oncology: Siemens Healthineers looking to exit non-core business for Rs 1,500 crore	0	7	09-07-2026
10	Draig Therapeutics Raises $65 Million Series B To Advance Neuropsychiatric Therapies	0	5	14-07-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 5. Источник: dealbreaker.com.